Clinical practice recommendations for the treatment of Alport syndrome: A statement of the Alport Syndrome Research Collaborative

Clifford E. Kashtan; Jie Ding; Martin Gregory; Oliver Gross; Laurence Heidet; Bertrand Knebelmann; Michelle Rheault; Christoph Licht

doi:10.1007/s00467-012-2138-4

Clinical practice recommendations for the treatment of Alport syndrome: A statement of the Alport Syndrome Research Collaborative

Clifford E. Kashtan, Jie Ding, Martin Gregory, Oliver Gross, Laurence Heidet, Bertrand Knebelmann, Michelle Rheault, Christoph Licht

Pediatrics - Nephrology

Research output: Contribution to journal › Review article › peer-review

114 Scopus citations

Abstract

We present clinical practice recommendations for the treatment of children with Alport syndrome who are not enrolled in clinical trials. Our goal is to promote early initiation of a standard therapeutic approach that will facilitate assessment of the safety and efficacy of the protocol. The treatment protocol is based on the reduction of proteinuria, intraglomerular pressure, and renal fibrosis via interference with the renin-angiotensin-aldosterone system.

Original language	English (US)
Pages (from-to)	5-11
Number of pages	7
Journal	Pediatric Nephrology
Volume	28
Issue number	1
DOIs	https://doi.org/10.1007/s00467-012-2138-4
State	Published - Jan 2013

Bibliographical note

Funding Information:
The Alport Syndrome Treatments and Outcomes Registry (C.K., M.G., M.R., C.L.) receives support from private donors and the Alport Syndrome Foundation ( www.alportsyndrome.org ). The European Alport Registry is supported by the Association pour l’Information et la Recherche sur les Maladies Rénales Génétiques (AIRG) (to O.G.) and the KfH Foundation Preventive Medicine (Fritz-Scheler Stipendium of the German Society of Nephrology) (to O.G.). The EARLY PRO-TECT Alport trial is funded by the German Ministry of Education and Research (O.G.).

Keywords

Aldosterone inhibitor
Alport syndrome
Angiotensin receptor blocker
Angiotensin-converting enzyme inhibitor
Proteinuria

Access

10.1007/s00467-012-2138-4

OpenUrl availability

Full text

Cite this

@article{8c45cd201253407fa20dd1cb188f14a2,

title = "Clinical practice recommendations for the treatment of Alport syndrome: A statement of the Alport Syndrome Research Collaborative",

abstract = "We present clinical practice recommendations for the treatment of children with Alport syndrome who are not enrolled in clinical trials. Our goal is to promote early initiation of a standard therapeutic approach that will facilitate assessment of the safety and efficacy of the protocol. The treatment protocol is based on the reduction of proteinuria, intraglomerular pressure, and renal fibrosis via interference with the renin-angiotensin-aldosterone system.",

keywords = "Aldosterone inhibitor, Alport syndrome, Angiotensin receptor blocker, Angiotensin-converting enzyme inhibitor, Proteinuria",

author = "Kashtan, {Clifford E.} and Jie Ding and Martin Gregory and Oliver Gross and Laurence Heidet and Bertrand Knebelmann and Michelle Rheault and Christoph Licht",

note = "Funding Information: The Alport Syndrome Treatments and Outcomes Registry (C.K., M.G., M.R., C.L.) receives support from private donors and the Alport Syndrome Foundation ( www.alportsyndrome.org ). The European Alport Registry is supported by the Association pour l{\textquoteright}Information et la Recherche sur les Maladies R{\'e}nales G{\'e}n{\'e}tiques (AIRG) (to O.G.) and the KfH Foundation Preventive Medicine (Fritz-Scheler Stipendium of the German Society of Nephrology) (to O.G.). The EARLY PRO-TECT Alport trial is funded by the German Ministry of Education and Research (O.G.). ",

year = "2013",

month = jan,

doi = "10.1007/s00467-012-2138-4",

language = "English (US)",

volume = "28",

pages = "5--11",

journal = "Pediatric Nephrology",

issn = "0931-041X",

publisher = "Springer Verlag",

number = "1",

}

TY - JOUR

T1 - Clinical practice recommendations for the treatment of Alport syndrome

T2 - A statement of the Alport Syndrome Research Collaborative

AU - Kashtan, Clifford E.

AU - Ding, Jie

AU - Gregory, Martin

AU - Gross, Oliver

AU - Heidet, Laurence

AU - Knebelmann, Bertrand

AU - Rheault, Michelle

AU - Licht, Christoph

N1 - Funding Information: The Alport Syndrome Treatments and Outcomes Registry (C.K., M.G., M.R., C.L.) receives support from private donors and the Alport Syndrome Foundation ( www.alportsyndrome.org ). The European Alport Registry is supported by the Association pour l’Information et la Recherche sur les Maladies Rénales Génétiques (AIRG) (to O.G.) and the KfH Foundation Preventive Medicine (Fritz-Scheler Stipendium of the German Society of Nephrology) (to O.G.). The EARLY PRO-TECT Alport trial is funded by the German Ministry of Education and Research (O.G.).

PY - 2013/1

Y1 - 2013/1

N2 - We present clinical practice recommendations for the treatment of children with Alport syndrome who are not enrolled in clinical trials. Our goal is to promote early initiation of a standard therapeutic approach that will facilitate assessment of the safety and efficacy of the protocol. The treatment protocol is based on the reduction of proteinuria, intraglomerular pressure, and renal fibrosis via interference with the renin-angiotensin-aldosterone system.

AB - We present clinical practice recommendations for the treatment of children with Alport syndrome who are not enrolled in clinical trials. Our goal is to promote early initiation of a standard therapeutic approach that will facilitate assessment of the safety and efficacy of the protocol. The treatment protocol is based on the reduction of proteinuria, intraglomerular pressure, and renal fibrosis via interference with the renin-angiotensin-aldosterone system.

KW - Aldosterone inhibitor

KW - Alport syndrome

KW - Angiotensin receptor blocker

KW - Angiotensin-converting enzyme inhibitor

KW - Proteinuria

UR - http://www.scopus.com/inward/record.url?scp=84870405692&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84870405692&partnerID=8YFLogxK

U2 - 10.1007/s00467-012-2138-4

DO - 10.1007/s00467-012-2138-4

M3 - Review article

C2 - 22461141

AN - SCOPUS:84870405692

SN - 0931-041X

VL - 28

SP - 5

EP - 11

JO - Pediatric Nephrology

JF - Pediatric Nephrology

IS - 1

ER -

Clinical practice recommendations for the treatment of Alport syndrome: A statement of the Alport Syndrome Research Collaborative

Abstract

Bibliographical note

Keywords

Access

OpenUrl availability

Other files and links

Fingerprint

Cite this